合成荷爾蒙市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品、給藥途徑、應用、最終用戶、地區和競爭進行細分，2020-2030 年預測

2024 年全球合成激素市場價值為 5.9565 億美元，預計在預測期內將經歷強勁成長，到 2030 年預計複合年成長率為 12.15%。這些荷爾蒙模仿內分泌腺產生的荷爾蒙的化學結構和功能，但是是在外部而不是在體內產生的。合成荷爾蒙有多種醫療用途，包括荷爾蒙替代療法 (HRT)、避孕和治療荷爾蒙相關疾病。它們由醫療保健提供者開立，用於解決荷爾蒙失衡問題、控制荷爾蒙相關疾病的症狀並提供避孕措施。合成激素通常用於治療更年期症狀、甲狀腺功能低下、激素相關癌症和生育控制等病症。這些荷爾蒙也是避孕藥、避孕貼、注射和子宮內避孕器 (IUD) 等避孕方法不可或缺的一部分。它們透過抑制排卵、增稠子宮頸黏液和改變子宮內膜來防止受精卵著床。

全球人口老化，特別是已開發國家人口老化，持續增加對合成荷爾蒙療法的需求。

主要市場促進因素

荷爾蒙失調盛行率不斷上升

主要市場挑戰

來自生物同質激素的競爭

生物同質激素的保險覆蓋範圍通常不如合成激素廣泛，這可能導致患者自付的費用更高。

主要市場趨勢

專注於個人化醫療

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：合成荷爾蒙市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依產品（胺基酸衍生物、胜肽類激素、類固醇激素）
  • 依給藥途徑（靜脈注射、鼻腔注射、口服、栓劑、外用）
  • 依用途分類（生長激素缺乏症、男性性腺功能低下、更年期、甲狀腺激素缺乏症）
  • 按最終用戶（醫院藥局、網路藥局、零售藥局）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美合成荷爾蒙市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第 7 章：歐洲合成荷爾蒙市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太地區合成荷爾蒙市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲合成激素市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲合成荷爾蒙市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 13 章：全球合成荷爾蒙市場：SWOT 分析

第 14 章：競爭格局

• Acerus Pharmaceuticals Corp.
• American Regent, Inc.
• Anhui Anke Biotechnology (Group) Co. Ltd.
• BioPartners, Inc
• Eli Lilly and Company
• Endo Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.
• IBSA Institut Biochimique SA
• Lupin Pharmaceuticals, Inc.
• Pfizer, Inc

第 15 章：策略建議

第16章 關於出版商,免責事項

The Global Synthetic Hormones Market was valued at USD 595.65 million in 2024 and is expected to experience robust growth during the forecast period, with a projected CAGR of 12.15% through 2030. Synthetic hormones are laboratory-manufactured versions of naturally occurring hormones in the human body. These hormones mimic the chemical structure and functions of those produced by the endocrine glands but are produced externally rather than within the body. Synthetic hormones serve various medical purposes, including hormone replacement therapy (HRT), contraception, and the treatment of hormone-related conditions. They are prescribed by healthcare providers to address hormonal imbalances, manage symptoms of hormone-related disorders, and provide contraception. Synthetic hormones are commonly used in the treatment of conditions such as menopause symptoms, hypothyroidism, hormone-related cancers, and fertility control. These hormones are also integral to contraceptive methods such as birth control pills, patches, injections, and intrauterine devices (IUDs). They function by inhibiting ovulation, thickening cervical mucus, and altering the uterine lining to prevent the implantation of a fertilized egg.

The aging global population, especially in developed countries, continues to contribute to the demand for synthetic hormone therapies.

Key Market Drivers

Increasing Prevalence of Hormonal Disorders

The growing incidence of hormonal disorders is a major driver for the expansion of the global synthetic hormones market. Hormonal imbalances can affect various physiological functions, leading to chronic diseases, reproductive health issues, metabolic disorders, and growth abnormalities. Approximately 60 to 80 million couples globally face infertility challenges, driving the demand for hormone-based treatments and assisted reproductive technologies. In addition, developing nations often experience significant gaps in access to contraception, creating new opportunities for expanded family planning solutions. The lack of safe reproductive healthcare results in 115,000 to 204,000 deaths annually due to unsafe abortion practices, underscoring the urgent need for enhanced healthcare infrastructure and investment in reproductive health services.

As the number of patients diagnosed with hormonal disorders rises, the demand for synthetic hormone therapies has increased. Conditions such as hypothyroidism, adrenal insufficiency, and menopause-related complications require long-term hormone replacement therapy (HRT). Synthetic hormones such as levothyroxine (for thyroid disorders), estrogen and progesterone (for menopause), and corticosteroids (for adrenal gland deficiencies) are essential in managing these conditions. The global population of postmenopausal women is expanding, with women aged 50 and older comprising 26% of the global female population in 2021, up from 22% a decade earlier. This demographic shift, coupled with increasing life expectancy, has led to greater demand for HRT, menopause management, and age-related healthcare innovations.

Diabetes, especially Type 1 diabetes, is another major hormonal disorder, impacting over 425 million people worldwide. With an expected increase in diabetes cases, the demand for synthetic insulin therapies is growing, which is a key segment within the synthetic hormones market. Pharmaceutical companies are investing in advanced insulin formulations and delivery systems, such as long-acting insulin analogs and smart insulin pens, to meet the demand for these therapies. Additionally, infertility due to lifestyle changes, stress, delayed pregnancies, and environmental factors has increased the need for assisted reproductive technologies (ART). Synthetic hormones such as gonadotropins, progesterone, and estrogen are essential in ART procedures like in-vitro fertilization (IVF) and ovulation induction therapies.

Key Market Challenges

Competition from Bioidentical Hormones

Bioidentical hormones, often perceived as more "natural" and less likely to cause adverse effects, present a growing competition to traditional synthetic hormones. Some consumers and healthcare providers prefer bioidentical hormones due to their customization and perceived safety benefits. Bioidentical hormones are often marketed aggressively, highlighting their advantages over synthetic hormones. Additionally, bioidentical hormones may be compounded individually by pharmacies to meet patients' specific needs, further increasing their appeal.

However, bioidentical hormones face different regulatory scrutiny than synthetic hormones and are sometimes classified as dietary supplements rather than pharmaceuticals, potentially leading to variations in quality and safety standards. Despite the ongoing debate about their safety and efficacy, bioidentical hormones may lack the extensive clinical data supporting synthetic hormones. Moreover, their compounded nature can result in variations in formulation and dosage, complicating the establishment of consistent treatment protocols.

Insurance coverage for bioidentical hormones is often less common than for synthetic hormones, which can result in higher out-of-pocket costs for patients.

Key Market Trends

Focus on Personalized Medicine

A key trend in the Global Synthetic Hormones Market is the growing emphasis on personalized medicine. Personalized medicine enables healthcare providers to tailor hormone therapy and dosages based on individual patients' hormonal imbalances, genetics, and responses to treatment. This approach aims to deliver more effective and efficient treatment outcomes, reducing adverse reactions and improving patient safety and compliance. By considering individual factors such as genetic predisposition and response to treatment, personalized medicine helps minimize unnecessary interventions and optimize hormone therapy.

In the treatment of conditions such as menopause or hypogonadism, personalized medicine allows for customized hormone replacement therapy (HRT) that targets the unique needs of each patient, ensuring better symptom relief and hormonal balance. Genetic testing can identify individuals at higher risk for hormone-related disorders or cancers, allowing for early intervention and prevention. Continuous patient monitoring allows for real-time adjustments to treatment plans, improving therapeutic outcomes. Additionally, personalized medicine can guide treatment decisions for hormone-related cancers, such as breast and prostate cancer, by identifying patients most likely to benefit from specific synthetic hormone therapies.

Key Market Players

• Acerus Pharmaceuticals Corp.
• American Regent, Inc.
• Anhui Anke Biotechnology (Group) Co. Ltd.
• BioPartners, Inc.
• Eli Lilly and Company
• Endo Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.
• IBSA Institut Biochimique SA
• Lupin Pharmaceuticals, Inc.
• Pfizer, Inc.

Report Scope

This report segments the Global Synthetic Hormones Market into the following categories, in addition to detailing the industry trends:

Synthetic Hormones Market, by Product:

• Amino Acid Derivatives
• Peptide Hormones
• Steroid Hormones

Synthetic Hormones Market, by Route of Administration:

• Intravenous
• Nasal
• Oral
• Suppository
• Topical

Synthetic Hormones Market, by Application:

• Growth Hormone Deficiency
• Male Hypogonadism
• Menopause
• Thyroid Hormone Deficiency

Synthetic Hormones Market, by End-User:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Synthetic Hormones Market, by Region:

• North America (United States, Canada, Mexico)
• Asia-Pacific (China, India, South Korea, Australia, Japan)
• Europe (Germany, France, United Kingdom, Spain, Italy)
• South America (Brazil, Argentina, Colombia)
• Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape

The report provides detailed company profiles of the major players in the Global Synthetic Hormones Market.

Available Customizations:

This Global Synthetic Hormones Market report offers customizations to meet specific company needs. The following options are available:

• Company Information: Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Synthetic Hormones Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Amino Acid Derivatives, Peptide Hormone, Steroid Hormones)
  • 5.2.2. By Route of Administration (Intravenous, Nasal, Oral, Suppository, Topical)
  • 5.2.3. By Application (Growth Hormone Deficiency, Male Hypogonadism, Menopause, Thyroid Hormone Deficiency)
  • 5.2.4. By End User (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Synthetic Hormones Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Route of Administration
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Synthetic Hormones Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Synthetic Hormones Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Synthetic Hormones Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Synthetic Hormones Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Route of Administration
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Synthetic Hormones Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Synthetic Hormones Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Synthetic Hormones Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. France Synthetic Hormones Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Synthetic Hormones Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Synthetic Hormones Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Route of Administration
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Synthetic Hormones Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Synthetic Hormones Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Synthetic Hormones Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Synthetic Hormones Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Synthetic Hormones Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Synthetic Hormones Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Route of Administration
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Synthetic Hormones Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Synthetic Hormones Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Synthetic Hormones Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Synthetic Hormones Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Route of Administration
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Synthetic Hormones Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Synthetic Hormones Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Synthetic Hormones Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Synthetic Hormones Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Acerus Pharmaceuticals Corp.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. American Regent, Inc.
• 14.3. Anhui Anke Biotechnology (Group) Co. Ltd.
• 14.4. BioPartners, Inc
• 14.5. Eli Lilly and Company
• 14.6. Endo Pharmaceuticals, Inc.
• 14.7. F. Hoffmann-La Roche Ltd.
• 14.8. IBSA Institut Biochimique SA
• 14.9. Lupin Pharmaceuticals, Inc.
• 14.10.Pfizer, Inc

15. Strategic Recommendations

16. About Us & Disclaimer